NEW YORK (GenomeWeb News) – Martin Madaus will take the CEO and chairman posts at Ortho Clinical Diagnostics upon the closure of The Carlyle Group's acquisition of OCD from Johnson and Johnson, which is expected to be mid-2014, OCD said this week.

Madaus recently was president, chairman, and CEO of Millipore, and is currently executive chairman of Quanterix's board of directors. He also is a director at Carlyle's portfolio companies PPD, Mettler Toledo, and Covidien.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.